Fierce Pharma10d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Stocktwits on MSN10d
Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight
Shares of Optinose, Inc. (OPTN) rocketed about 55% on Thursday after privately held Paratek Pharmaceuticals announced that it ...
Optinose to be acquired by Boston-based Paratek Pharmaceuticals in potential $330M deal
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Zacks Investment Research on MSN9d
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...
Business Insider10d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which ...
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will ...
The National Law Review11d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire ...